Primary containers with improved protein drug stability and lower immune response

A primary drug container comprising:

• a wall having an internal surface defining a lumen;
• and
• a PECVD drug-contact coating on or adjacent to the internal surface and positioned to contact a fluid in the lumen, in which the drug-contact coating consists essentially of SiOxCyHz, in which
• x is between 0.5 and 2.4 as measured by x-ray photoelectron spectroscopy (XPS),
• y is between 0.6 and 3 as measured by XPS;
• and
• z is between 2 and 9 as measured by Rutherford backscattering;
• and
• a polypeptide composition contained in the lumen in contact with the PECVD drug-contact coating;
• the primary drug container containing between a lower limit of 1,000, alternatively 2,000, alternatively 3,000, and an upper limit of 100,000, alternatively 75,000, alternatively 50,000, alternatively 25,000, alternatively 20,000, alternatively 18,000, alternatively 16,000, alternatively 14,000, alternatively 12,000, alternatively 10,000, alternatively 8,000, alternatively 6,000, alternatively 4,000, alternatively 3,000 particles having effective spherical diameters greater than 2 and no more than 10 micrometers (μm) per mL of solution;
• in which the particle count is measured by filling the primary drug container with 1 mg/mL IVIg in 250 mM glycine pH 4.25 with 0.02% (v/v) PS20 and rotating the primary container end-over end at room temperature for 10 days, causing the air bubble in the headspace gap to move from one end of syringe to other end with each rotation, and testing the processed contents of the primary drug container for particle concentrations using flow imaging microscopy.